Kelley Shannon T sold $342K of MDGL

Kelley Shannon T (General Counsel) sold 664 shares of MADRIGAL PHARMACEUTICALS, INC. (MDGL) at $514.97 ($0.34M total) on 2026-08-17.

Original reporting
SEC EDGAR · Kelley Shannon T
Published Aug 20, 2026, 8:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 8:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MDGL
Bearish
medium confidence
Mentioned
$MDGL
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MDGLBearishLow
01

Why it matters

The sale reduces insider ownership modestly; market may view as neutral to slightly negative.

02

Market read

Small insider sale with limited price impact; traders may monitor for further insider activity.

03

What to watch

Potential upcoming clinical data or regulatory events not disclosed.

Relevance 4/10Novelty 4/10Timing: filed 2026-08-20

Background

Form 4 filing reports insider transactions for publicly traded companies.

Company-level read

Ticker impact

$MDGLBearishMedium confidence
Context

General Counsel Kelley Shannon T sold 664 shares for $341,940, reducing her stake to 11,474 shares.

Expected impact

Potential slight downward pressure in short term.

Evidence & confidence

Form 4 filing is primary source; sale size under $1M limits material impact.

Market effects

Minimal effect on biotech sector; typical insider sell.

No regional impact.

Low global relevance.

Counterpoint

Insider may be diversifying; sale does not reflect company fundamentals.

Key entities

  • Madrigal Pharmaceuticals, Inc.

    Biotech firm developing therapies for liver disease.

  • Kelley Shannon T

    General Counsel of Madrigal Pharmaceuticals.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MDGLMedAI 8/10

BAKER BROS. ADVISORS LP (BAKER FELIX, BAKER JULIAN) purchased $35.0M of MDGL (indirect holdings)

BAKER BROS. ADVISORS LP purchased 91,806 indirectly-held shares of MADRIGAL PHARMACEUTICALS, INC. (MDGL) at an average of $381.49 ($366.99–$396.61, $35.02M total) across 5 trades over 2026-11-04 to 2026-11-06. Filed jointly with Baker Bros. Advisors (GP) LLC (Director), BAKER FELIX (Director), BAKER JULIAN (Director), 667, L.P. (Director) and Baker Brothers Life Sciences LP (Director).

$MDGLMed

Madrigal reports real-world data on liver disease drug Rezdiffra

Madrigal Pharmaceuticals (MDGL) presented real-world data on its liver disease drug Rezdiffra at a liver disease conference. Studies showed 37% to 55% of patients achieved at least 25% improvement in liver stiffness after a year, with 83% to 93% improving or stabilizing. Safety findings were consistent with clinical trials. Rezdiffra is approved for treating adults with MASH.

$MDGLMedAI 8/10

Madrigal (MDGL) Q3 2026 Earnings Call Transcript

Madrigal Pharmaceuticals (MDGL) reported Q3 2026 net sales of $431M, up 50% YoY, driven by demand for Rezdiffra. The company had 55,850 active Rezdiffra patients, nearly double the previous year. Madrigal expects the U.S. F2/F3 MASH market to grow 30% by year-end, with Rezdiffra penetrating about 1% of the total opportunity.